Altay Therapeutics, a biotechnology company focused on developing therapies for facioscapulohumeral muscular dystrophy (FSHD), has announced the successful closure of a US$37 million Series A financing round. This funding round was co-led by prominent investors Sound Bioventures and HealthCap and saw participation from additional investors including Fountain Healthcare Partners, Biogen New Ventures, Pappas Capital, and Global BioAccess Fund. SOLVE FSHD, a venture-philanthropy organization dedicated to accelerating therapies for FSHD, has been instrumental in supporting Altay Therapeutics through previous funding initiatives, including nearly US$7 million in seed investment. With this new funding, Altay plans to advance the development of DX5057, a potential therapy for FSHD, a genetic disorder that leads to muscle weakness and atrophy. This financing milestone underlines the growing interest and commitment to addressing rare diseases through innovative therapeutic solutions in the biotechnology sector.
Analyzed Canadian Outlets (2)
1 headline · wire copies grouped